<DOC>
	<DOC>NCT00134940</DOC>
	<brief_summary>The purpose of this observational protocol is to evaluate the use of everolimus in routine clinical practice for heart transplants. Primary outcome measures: incidence of acute rejection episodes Secondary outcomes: safety</brief_summary>
	<brief_title>Post-marketing Study to Collect Safety Data in Heart Transplant Patients Receiving Everolimus</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Cardiac transplant recipients Discharged alive from hospital Must be receiving everolimus Patients not treated with everolimus beginning within 2 weeks after receiving a heart transplant Other inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Transplantation, heart</keyword>
	<keyword>Organ transplant</keyword>
</DOC>